Canada markets open in 4 hours 15 minutes

Anika Therapeutics, Inc. (ANIK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
24.76+0.19 (+0.77%)
At close: 04:00PM EDT
25.24 +0.48 (+1.94%)
After hours: 04:08PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close24.57
Open24.81
Bid24.71 x 100
Ask24.91 x 100
Day's Range24.51 - 24.84
52 Week Range16.54 - 28.67
Volume34,800
Avg. Volume74,398
Market Cap367.154M
Beta (5Y Monthly)0.73
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Anika Enters into Cooperation Agreement with Caligan Partners

    Appoints Joseph Capper and William Jellison to Board of DirectorsAnnounces New $40 Million Share Repurchase Program BEDFORD, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that it has entered into a cooperation agreement with Caligan Partners LP (“Caligan”). As part of the agreement, Joseph Capper, CEO of MIMEDX, and William Jellison, former CFO of Stryker, have been appointed

  • GlobeNewswire

    Anika Announces CFO Transition

    Steve Griffin Appointed Chief Financial Officer, Effective June 3, 2024BEDFORD, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that it has appointed Steve Griffin as the Company’s Executive Vice President, Chief Financial Officer (“CFO”) and Treasurer, effective June 3, 2024. He succeeds Michael Levitz, who has decided to step down as CFO after almost four years with the compa

  • GlobeNewswire

    Anika Reports First Quarter 2024 Financial Results

    Revenue up 7% on growing demand and favorable order timing; On-track for 2024 revenue guidance Cost reduction initiatives complete; On-track to achieve 2024 adjusted EBITDA guidance of $25-30 million, up over 75% at the midpoint BEDFORD, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its first quarter ended March 31, 2024. First Quarter 2024 Financial Summ